Accreditation Information

ACCME
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Contact Hours: 1.0, and will be eligible for pharmacology credit.

ABIM MOC Part II
Successful completion of this CME activity, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. By attending this activity and providing your ABIM number & Date of Birth, you authorize BUSM CME office to report your information to the ACCME so that we may process your MOC Part II credit on your behalf.

ABIM MOC

 

Needs Statement

Ulcerative Colitis (UC) is a chronic, inflammatory gastrointestinal disease that can have a significant negative impact on the lives of patients. Advances in treatments that are available give patients today a better chance of achieving remission, yet many patients continue to live with symptoms of moderate-to-severe disease. Several gaps in care exist that prevent patients from achieving this treatment goal.

Appropriate treatment for a patient’s disease severity is often not used and evidence-based algorithms are not followed by all gastroenterologists. The introduction of anti-TNF agents revolutionized treatment of UC and now anti-integrin therapies are available, giving patients expanded options for individualized treatment. However, some gastroenterologists are still using traditional step-up treatment strategies in patients with moderate-to-severe UC that delay the initiation of biologic agents in patients who would benefit from their use earlier in therapy. Also, loss of response or primary non-response can occur as well as intolerance to therapy. Gastroenterologists need to be familiar with methods to manage these patients and be aware that new options are in development that could offer alternatives to the agents that are currently used. 

Implementing quality measures and tracking this information can assist gastroenterologists with improving the quality of UC care. Real-world data is becoming a useful tool in assessing overall treatment patterns and applying this data can improve care processes. It can also be useful in evaluating treatment options outside of the controlled clinical trial setting to provide more information about the efficacy, safety, and predictors of response to treatment. Because there are several areas for improvement in UC treatment among gastroenterologists, it is important that clinicians be aware of these deficits and make efforts to examine their own practice to improve the care of their patients.

 

Objectives

At the conclusion of this activity, participants will be able to (or better able to):

  1. Identify patients with moderate-to-severe Ulcerative Colitis (UC) who are at high risk for adverse outcomes including surgery and select appropriate treatment for these patients.
  2. Describe reasons for non-response to UC therapy and be able to adjust treatment regimens using evidence-based algorithms and data for various treatment options to help patients attain remission.
  3. Discuss the safety, efficacy, place in therapy, and impact on practice of biologic agents and small molecules that are currently in clinical trials for the treatment of UC.
  4. Analyze real-world data to improve the quality of care provided for UC in clinical practice, scrutinize the safety and efficacy of various treatment options, and review data to find patterns that can provide insights into clinical challenges in UC.

Target Audience

This activity is intended for gastroenterologists, primary care physicians, NP/PAs, nurses and other clinicians who are attending the 2017 ACG Postgraduate Regional Courses, and have an interest in the treatment/management of Ulcerative Colitis (UC).

Faculty Disclosure

Disclosure Policy

It is the policy of Boston University School of Medicine Department of Continuing Medical Education, that faculty disclose to program participants any real or apparent conflict of interest. In addition, the faculty is asked to disclose any discussion pertaining to the unapproved use of pharmaceuticals and devices. Complete disclosure information will be available on site in the printed course materials.

Faculty Disclosures

Course Director

Francis Farraye, MD. MSc is a consultant for AbbVie, Braintree, Celgene, Ferring, Janssen, Merck, Pfizer, Puma and Takeda, receives grant/research support from Prometheus, is a stockholder of Celleutix and DSMB for Mesoblast and Protagonist.

Dr. Farraye plans to discuss unlabeled/investigational uses of Azathioprine.

Faculty

David Rubin, MD is a consultant for and receives grant support from AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Shire, Takeda and UCB Pharma, and is a consultant for Abegenomics, Celegene Corporation, Forward Pharma, Lockwood Group, Miraca Life Sciences, Pfizer, Samsung Bioepis and Sandox Pharmaceuticals.  Dr. Rubin is on the Board of Trustees for the American College of Gastroenterology, Co-Founder of the non-profit medical education entity Cornerstones Health, Inc and Co-Founder of GoDuRn, LLC. 

Dr. Rubin does not plan to discuss unlabeled/investigational uses of a commercial product.

CNE Course Advisor

Beth-Ann Norton, MS, RN, ANP-BC does not have anything to disclose with regard to commercial interest

Planning Committee

Co-Course Director Bret Lashner, MD, Lead Nurse Planner, Patti-Ann Collins, DNP, MSN, MBA/RN and BU Program Managers Dana Frazier, BBA, CHCP and Joanna Krause, MPH do not have anything to disclose with regards to commercial interest.

Independent Reviewer (for ABIM MOC part 2 requirements): Sharmeel Wasan, MD does not have anything to disclose in regards to commercial interest.